Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Intel Corp (INTC) Price & Performance

DexCom, Inc.Trade
Intel CorpTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Intel Corp — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while Intel Corp trades at $99.65 (market cap $492.85B). The key difference: Intel Corp is far larger — about 14.6× DexCom, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

DXCMINTC
Market Cap
$33.79B$492.85B
Sector
HealthTechnology
52-Week High
$89.53$140.94
52-Week Low
$54.84$21.81
Enterprise Value
$33.24B$513.66B
Volume
43,552,012
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.

The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.

Intel Corp

Intel (INTC) trades at $97.52, down 4.06% today amid a $20 billion stock offering announcement. Despite recent earnings beats, the stock faces pressure from dilution concerns while showing strong revenue growth in data center and AI segments. Technical indicators are bullish on moving averages but neutral on oscillators, with key resistance at $100. Fundamentals reveal a mixed picture with negative net income margins but improving operational cash flow trends.

The outlook remains cautiously optimistic with a $116.67 analyst price target suggesting 20% upside, though execution risks in foundry losses and competitive pressures persist. Investors should weigh the growth potential in AI against near-term dilution and margin challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

Read more on INTC